While this has shown promise, in murine breast cancer models, a rebound effect was shown after the withdrawal of anti-CCL2 treatment, increasing the infiltration of bone-marrow monocytes into the tumor and accelerating lung metastasis [135]. Here, CCL2 is linked to breast carcinoma.